Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Jazz Pharmaceuticals PLC

Current price
121.45 USD +2.61 USD (+2.20%)
Last closed 119.11 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 7 498 796 544 USD
Yield for 12 month -19.55 %
21.11.2021 - 28.11.2021

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland. Address: Waterloo Exchange, Dublin, Ireland, 4


WallStreet Target Price

195 USD

P/E ratio


Dividend Yield

2.75 %

Current Year

+3 659 374 000 USD

Last Year

+3 094 238 000 USD

Current Quarter

+972 140 000 USD

Last Quarter

+957 317 000 USD

Current Year

+3 118 857 000 USD

Last Year

+2 653 478 000 USD

Current Quarter

+869 987 000 USD

Last Quarter

+859 780 000 USD

Key Figures JAZZ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 1 653 912 960 USD
Operating Margin TTM 17.73 %
PE Ratio 143.506
Return On Assets TTM 5.96 %
PEG Ratio 86.9073
Return On Equity TTM 2.57 %
Wall Street Target Price 195 USD
Revenue TTM 3 794 392 064 USD
Book Value 55.44 USD
Revenue Per Share TTM 59.84 USD
Dividend Share
Quarterly Revenue Growth YOY 3.3 %
Dividend Yield 2.75 %
Gross Profit TTM 3 392 249 000 USD
Earnings Share 0.83 USD
Diluted Eps TTM 0.83 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY 175.7 %
Profit Margin 2.11 %

Dividend Analytics JAZZ

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History JAZZ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 2.75 %
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation JAZZ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 143.506
Forward PE 6.0827
Enterprise Value Revenue 3.0852
Price Sales TTM 1.9763
Enterprise Value EBITDA 14.3835
Price Book MRQ 2.1489

Financials JAZZ

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators JAZZ

For 52 weeks

111.25 USD 160.96 USD
50 Day MA 126.75 USD
Shares Short Prior Month 2 741 982
200 Day MA 133.29 USD
Short Ratio 2.79
Shares Short 2 566 914
Short Percent 4.69 %